CURRENT TREATMENT OPTIONS FOR COVID - 19
The current pandemic of Coronavirus Disease 2019 (COVID-19) caused about 350 000 deaths in world. Currently, there are no proven effective vaccines or therapeutic agents against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Current clinical management includes supportive treatment and infection prevention and control measures. Research and clinical data regarding suggest a potential list of repurposed drugs with appropriate pharmacological effects and therapeutic efficacies in treating COVID-19 patients. In this review, we will update and summarize the most common and plausible drugs for the treatment of COVID-19 patients. These drugs and therapeutic agents include antiviral agents (favipiravir, remdesivir, hydroxychloroquine-chloroquine, lopinavir/ritonavir) and immunomodulatory agents (tocilizumab, tnf alpha inhibitors, corticosteroids, mesenchymal stem cell), among others.
Esma Eren1, Aysegul Ulu Kiliç2
1 Kayseri City Hospital, Infectious Disease Clinic, Kayseri, Turkey;
2 Erciyes University, Faculty of Medicine, Department of Infectious Disease and Clinical Microbiology, Kayseri, Turkey.
1. Tyrrell D.A., Bynoe M.L. Cultivation of viruses from a high proportion of patients with colds // Lancet. 1966; 1: 76–77.
2. GISAID Global Initiative on Sharing All Influenza Data. Phylogeny of SARS-like betacoronaviruses including novel coronavirus (nCoV). (Available from: https://nextstrain. org/groups/blab/sars-like-cov).
3. Gorbalenya A.E., Baker S.C., Baric R.S., de Groot R.J., Drosten C., Gulyaeva A.A., et al. (March 2020). "The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2" // Nature Microbiology. 5 (4): 536–544.
4. Cucinotta D., Vanelli M. WHO Declares COVID-19 a Pandemic // Acta Biomed. 2020;91(1):157‐160.
5. Li Q., Guan X., Wu P., Wang X., Zhou L., Tong Y., Ren R., Leung K., Lau E., Wong J. Y., Xing X., Xiang N., Wu Y., Li C., Chen Q., Li D., Liu T., Zhao J., Liu M., Tu W., … Feng Z. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia // The New England journal of medicine. 2020;382(13); 1199–1207.
6. Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., Zhao, Y., Li, Y., Wang, X., & Peng, Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China // JAMA. 2020; 323(11):1061–1069.
7. Rothe C., Schunk M., Sothmann P., Bretzel G., Froeschl G., Wallrauch C., Zimmer T., Thiel V., Janke C., Guggemos W., Seilmaier M., Drosten C., Vollmar P., Zwirglmaier K., Zange S., Wölfel R., Hoelscher M. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany // N Engl J Med. 2020 ; 5:382
8. Wu Z., Mc Googan J.M. (2020). Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention // JAMA. 2020;10-1001
9. Lauer S.A., Grantz K.H., Bi Q., Jones F.K., Zheng Q., Meredith H.R., Azman A.S., Reich N.G., Lessler J. (2020). The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application // Annals of internal medicine. 2020; 172(9):577–582.
10. Hani C., Trieu N.H., Saab I., Dangeard S., Bennani S., Chassagnon G., Revel M.P. (2020). COVID-19 pneumonia: A review of typical CT findings and differential diagnosis // Diagnostic and interventional imaging, 101(5), 263–268. https://doi.org/10.1016/j.diii.2020.03.014
11. Cox M.J., Loman N., Bogaert D., O’Grady J. Coinfections: potentially lethal and unexplored in COVID-19 // Lancet Microbe. 2020; 1: 89–91.
12. Furuta Y., Komeno T., Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase // Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 2017; 93: 449–463.
13. Shiraki K., Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections // Pharmacology & Therapeutics; 2020:107512.
14. Sissoko D., Laouenan C., Folkesson E., M'Lebing A.B., Beavogui A.H., Baize S. et al. Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea // PLoS Med. 2016;13(4):e1002009.
15. Zhao Y., Harmatz J.S., Epstein C.R., et al. Favipiravir inhibits acetaminophen sulfate formation but minimally affects systemic pharmacokinetics of acetaminophen // Br J Clin Pharmacol. 2015;80(5):1076‐1085. doi:10.1111/bcp.12644
16. Cai Q., Yang M., Liu D., Chen J., Shu D., Xia J., Liao X., Gu Y., Cai Q., Yang Y., Shen C., Li X., Peng L., Huang D., Zhang J., Zhang S., Wang F., Liu J., Chen L., Chen S.et al. Experimental Treatment with Favipiravir for COVID-19:An Open-Label Control Study // Engineering. 2020;10.1016
17. Brown A.J., Won J.J., Graham R.L., et al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase // Antivir Res. 2019;169:104541.
18. Mulangu S., Dodd L.E., Davey Jr. R.T., et al. A randomized, controlled trial of Ebola virus disease therapeutics // N Engl J Med. 2019;381:2293e303.
19. Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M., Shi Z., Hu Z., Zhong W., Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro // Cell Res. 2020;30(3):269‐271.
20. Summary on compassionate use remdesivir Gilead. https://www.ema.europa.neu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en. pdf (Accessed May 5, 2020).
21. Grein J., Ohmagari N., Shin D., et al. Compassionate use of remdesivir for patients with severe COVID-19 // N Engl J Med 2020; Apr 10. doi:10.1056/NEJMoa2007016.
22. Wang Y., Zhang D., Du G., Du R., Zhao J., Jin Y., Fu S., Gao L., Cheng Z., Lu Q., Hu Y., Luo G., Wang K., Lu Y., Li H., Wang S., Ruan S., Yang C., Mei C., Wang Y., … Wang C. (2020). Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial // Lancet (London, England). 2020;395(10236): 1569–1578.
23. Beigel J.H., Tomashek K.M., Dodd L.E., Mehta A.K., Zingman B.S., Kalil A.C., Hohmann E., Chu H.Y., Luetkemeyer A., Kline S., Lopez de Castilla D., Finberg R.W., Dierberg K., Tapson V., Hsieh L., Patterson T.F., Paredes R., Sweeney D.A., Short W.R., Touloumi G., … ACTT-1 Study Group Members (2020). Remdesivir for the Treatment of Covid-19 - Preliminary Report // The New England journal of medicine, 10.1056/NEJMoa2007764. Advance online publication. https://doi.org/10.1056/NEJMoa2007764
24. "Frequently Asked Questions on the Emergency Use Authorization for Remdesivir for Certain Hospitalized COVID‐19 Patients" (PDF). U.S. Food and Drug Administration (FDA). 1 May 2020. Retrieved 1 May 2020. 256.
25. de Wilde A.H., Jochmans D., Posthuma C.C., et al. Screening of an FDAapproved compound library identifi es four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture // Antimicrob Agents Chemother. 2014; 58(8):4875–4884. doi:10.1128/AAC.03011-14
26. Chu C.M., Cheng V.C., Hung I.F., et al; HKU/UCH SARS Study Group. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical fi ndings // Thorax. 2004; 59(3):252–256. doi:10.1136/ thorax.2003.012658.
27. Cao B., Wang Y., Wen D., Liu W., Wang J., Fan G., Ruan L., Song B., Cai Y., Wei M., Li X., Xia J., Chen N., Xiang J., Yu T., Bai T., Xie X., Zhang L., Li C., Yuan Y., … Wang C. (2020). A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19 // The New England journal of medicine, 382(19), 1787–1799. https://doi.org/10.1056/NEJMoa2001282
28. Ashish Chandwani and Jonathan Shuter. Lopinavir / ritonavir in the treatment of HIV-1 infection: a review // Ther Clin Risk Manag. 2008 Oct; 4(5): 1023–1033. Published online 2008 Oct. doi: 10.2147/tcrm.s3285.
29. Plantone D., Koudriavtseva T. (2018). Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review // Clinical drug investigation,38(8), 653–671. https://doi.org/10.1007/s40261-018-0656-y
30. Ao X., Ye F., Zhang M., Cui C., Huang B., Niu P., Liu X., Zhao L., Dong E., Song C., Zhan S., Lu R., Li H., Tan W., Liu D. (2020). In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) // Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, ciaa237. Advance online publication. https://doi.org/10.1093/cid/ciaa237
31. Chen J., Liu D., Liu L., Liu P., Xu Q., Xia L., Ling Y., Huang D., Song S., Zhang D., Qian Z., Li T., Shen Y., Lu H. Zhejiang da xue xue bao. Yi xue ban // Journal of Zhejiang University. Medical sciences, 2020. 49(2), 215–219.
32. Gautret P., Lagier J.C., Parola P., Hoang V.T., Meddeb L., Mailhe M., Doudier B., Courjon J., Giordanengo V., Vieira V.E., Dupont H.T., Honoré S., Colson P., Chabrière E., La Scola B., Rolain J.M., Brouqui P., Raoult D. (2020). Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial // International journal of antimicrobial agents, 105949. Advance online publication. https://doi.org/10.1016/j.ijantimicag.2020.105949.
33. Mandeep R. Mehra, Sapan S. Desai, Frank Ruschitzka, Amit N. Patel. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. 2020
34. WHO Director-General's opening remarks at the media briefing on COVID-19 - 25 May 2020
35. Channappanavar R., Perlman S. (2017). Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology // Seminars in immunopathology, 39(5), 529–539. https://doi.org/10.1007/s00281-017-0629-x
36. Zhang X., Song K., Tong F., Fei M., Guo H., Lu Z., Wang J., Zheng C. (2020). First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab // Blood advances, 4(7), 1307–1310. https://doi.org/10.1182/bloodadvances.2020001907
37. Luo P., Liu Y., Qiu L., Liu X., Liu D., Li J. (2020). Tocilizumab treatment in COVID-19: A single center experience // Journal of medical virology, 10.1002/jmv.25801. Advance online publication.
38. Tobinick E. TNF-alpha inhibition for potential therapeutic modulation of SARS coronavirus infection. Current Medical Research and Opinion. 2004;20(1):39-40. DOI: 10.1185/030079903125002757.
39. Atanasova K., Van Gucht S., Van Reeth K. Anti-TNF-alpha therapy does not ameliorate disease in a model of acute virus-endotoxin mediated respiratory disease in pigs // Veterinary immunology and immunopathology. 2010; 137(1-2), 12–19.
40. DeDiego M.L., Nieto-Torres J.L. Regla-Nava J.A., et al. Inhibition of NF-κB-mediated inflammation in severe acute respiratory syndrome coronavirus-infected mice increases survival // J Virol. 2014; 88: 913–924.
41. Sibila O., Agusti C., Torres A. Corticosteroids in severe pneumonia // Eur Respir J. 2008; 32:259–264.
42. Liu K., Fang Y.Y., Deng Y., Liu W., Wang M.F., Ma J.P., et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province // Chin Med J. (2020). doi: 10.1097/CM9.0000000000000744
43. Wu C., Chen X., Cai Y., et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China [published online ahead of print, 2020 Mar 13] // JAMA Intern Med. 2020;e200994.
44. Ling, Y., Xu, S. B., Lin, Y. X., Tian, D., Zhu, Z. Q., Dai, F. H., Wu, F., Song, Z. G., Huang, W., Chen, J., Hu, B. J., Wang, S., Mao, E. Q., Zhu, L., Zhang. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients // Chin Med J (Engl). 2020;133(9):1039‐1043.
45. Zha L., Li S., Pan L., Tefsen B., Li Y., French N., Chen L., Yang G., Villanueva E.V. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19) // Med J Aust. 2020;212(9):416‐420.
46. Iwabuchi K., Yoshie K., Kurakami Y., Takahashi K., Kato Y., Morishima T. Therapeutic potential of ciclesonide inahalation for COVID-19 pneumonia: Report of three cases // J Infect Chemother. 2020;26(6):625‐632.
47. van Griensven J., Edwards T., de Lamballerie X., et al; Ebola-Tx Consortium. Evaluation of convalescent plasma for Ebola virus disease inGuinea // N Engl J Med. 2016;374(1):33-42.
48. Hung I.F., To K.K., Lee C.K., et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection // Clin Infect Dis. 2011;52(4):447-456.
49. Burnouf T., Radosevich M. Treatment of severe acute respiratory syndrome with convalescent plasma // Hong Kong Med J. 2003;9(4):309.
50. Cheng Y., Wong R., Soo Y.O., et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24 (1):44-46.
51. Mair-Jenkins J., Saavedra-Campos M., Baillie J.K., et al; Convalescent Plasma Study Group. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratorymeta-analysis // J Infect Dis. 2015;211(1):80-90.
52. Rajendran K., Krishnasamy N., Rangarajan J., Rathinam J., Natarajan M., Ramachandran A. Convalescent plasma transfusion for the treatment of COVID‐19: Systematic review // J Med Virol. 2020; 1–9.
53. Golchin A., Farahany T.Z. Biological Products: Cellular Therapy and FDA Approved Products // Stem Cell Rev and Rep. 2019; 15, 166–175.
54. Mei S.H., Haitsma J.J., Dos Santos C.C., Deng Y., Lai P.F., Slutsky A.S., et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis // Am J Respir Crit Care Med. 2010;182(8):1047–57.
55. Khatri M., Richardson L.A., Meulia T. Mesenchymal stem cell-derived extracellular vesicles attenuate influenza virus-induced acute lung injury in a pig model // Stem Cell Res Therapy. 2018;9(1):17.
56. Li F., Karlsson H. Antiviral effect of IDO in mouse fibroblast cells during influenza virus infection // Viral Immunol. 2017;30(7):542–4.
57. Mao R., Zhang J., Jiang D., Cai D., Levy J.M., Cuconati A., et al. Indoleamine 2,3-dioxygenase mediates the antiviral effect of gamma interferon against hepatitis B virus in human hepatocyte-derived cells // J Virol. 2011;85(2):1048–57.
58. Adams O., Besken K., Oberdorfer C., Mac Kenzie C.R., Takikawa O., Daubener W. Role of indoleamine-2,3-dioxygenase in alpha/beta and gamma interferon-mediated antiviral effects against herpes simplex virus infections // J Virol. 2004;78(5):2632–6.
59. Obojes K., Andres O., Kim K.S., Daubener W., Schneider-Schaulies J. Indoleamine 2,3-dioxygenase mediates cell type-specific anti-measles virus activity of gamma interferon // J Virol. 2005;79(12):7768–76.
60. Moodley Y., Atienza D., Manuelpillai U., Samuel C.S., Tchongue J., Ilancheran S., et al. Human umbilical cord mesenchymal stem cells reduce fibrosis of bleomycin-induced lung injury // Am J Pathol. 2009;175(1):303–13.
61. Leng Z., Zhu R., Hou W., Feng Y., Yang Y., Han Q., Shan G., Meng F., Du D., Wang S., Fan J., Wang W., Deng L., Shi H., Li H., Hu Z., Zhang F., Gao J., Liu H., Li X., … Zhao R. Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia // Aging and disease. 2020;11(2), 216–228.
Количество просмотров: 518
Категория статей:
Актуальная тема
Библиографическая ссылка
Eren E., Kiliç A.U. Current Treatment Options for COVID-19 // Nauka i Zdravookhranenie [Science & Healthcare]. 2020, (Vol.22) 3, pp. 5-11. doi 10.34689/SH.2020.22.3.001Авторизируйтесь для отправки комментариев